NASDAQ: AYTUAytu Biopharma Inc Stock
$1.95+0.00 (+0%)
Updated Jun 13, 2025
AYTU Price
$1.95
Fair Value Price
N/A
Market Cap
$12.03M
52 Week Low
$0.95
52 Week High
$2.99
P/E
9.75x
P/B
0.34x
P/S
0.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$69.22M
Earnings
$1.64M
Gross Margin
68.6%
Operating Margin
14.59%
Profit Margin
2.4%
Debt to Equity
2.56
Operating Cash Flow
-$6M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AYTU Overview
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AYTU's potential to beat the market
- AYTU doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
AYTU
RankedUnranked of 59
RankedUnranked of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.93 | A | |
| $5.24 | A | |
| $6.88 | A |
Be the first to know about important AYTU news, forecast changes, insider trades & much more!
AYTU News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AYTU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AYTU is good value based on its earnings relative to its share price (9.75x), compared to the US market average (31.36x)
P/E vs Market Valuation
AYTU is good value based on its earnings relative to its share price (9.75x), compared to the US Drug Manufacturers - Specialty & Generic industry average (-23.1x)
P/E vs Industry Valuation
AYTU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more AYTU due diligence checks available for Premium users.
Valuation
AYTU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.75x
Industry
-23.1x
Market
31.36x
AYTU is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AYTU is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AYTU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
2.26x
AYTU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AYTU's financial health
Profit margin
Revenue
$18.5M
Net Income
$4.0M
Profit Margin
21.6%
AYTU's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AYTU's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$124.2M
Liabilities
$89.3M
Debt to equity
2.56
AYTU's short-term assets ($72.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AYTU's short-term assets ($72.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AYTU's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AYTU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.5M
Investing
-$69.0k
Financing
$4.3M
AYTU's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AYTU vs Pharmaceutical Stocks
Aytu Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.